Chordia Therapeutics Inc.
Chordia Therapeutics株式会社
Japan
Development of pharmaceutical drugs
Clinical testing services
Licensing of drug candidates
Kanagawa Prefecture, Fujisawa City, Muraoka Higashi 2-chome, 26-1
Hiroshi Miyake
845,000,000 JPY (8 100 millionJPY)
22 people
Company name
Group
Parent
Subsidiary
Customer
Supplier
Alliance
Bank
Shareholder
Loading...
Loading the relationship graph...
12 entries
| Date | Description |
|---|
| 2017-10-12 |
Establishment of Chordia Therapeutics Inc. |
| 2017-10-12 |
Establishment of Chordia Therapeutics Inc. |
| 2017-11 |
Fundraising of approximately 1.2 billion yen in Series A round |
| 2018-11 |
Start of Phase 1 trial in Japan for Rogocekib |
| 2019-03 |
Fundraising of approximately 3 billion yen in Series B round |
| 2020-11 |
Acquisition of exclusive worldwide rights for 4 programs from Takeda Pharmaceutical Company |
| 2020-12 |
License-out of MALT1 inhibitor drug with Ono Pharmaceutical (rights returned on April 28, 2025) |
| 2022-05 |
Fundraising of approximately 4 billion yen in Series C round |
| 2023-02 |
Initiation of Phase 1/2 trials in the United States |
| 2024-06 |
Listed on the Tokyo Stock Exchange Growth Market |
| 2025-09 |
Okaya University appointed Mr. Yoichi Oka as CFO, currently serving. After working in audit at a major auditing firm, he has led M&A advisory services and supervised organizations as head of corporate management departments, leading the formulation and execution of financial strategies. |
| 2026-01 |
Mr. Yoshiyuki Tanaka was appointed Chief Medical Officer (CMO) of Chordia Therapeutics Inc. in January 2026, currently serving. |
1021001063330
| Trade name | Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 |
|---|
| Trade name (kana) | コーディアセラピューティクス |
|---|
| Name in English | |
|---|
| Corporation type | 301 |
|---|
| Address | 〒251-0012 神奈川県藤沢市村岡東２丁目２６番地の１ |
|---|
| Postal code | 2510012 |
|---|
| Prefecture code | 14 |
|---|
| City code | 205 |
|---|
| Address outside Japan | |
|---|
| Prefecture in English | |
|---|
| City in English | |
|---|
| Address outside Japan in English | |
|---|
| Corporate number assignment date | 2017-10-19 |
|---|
| Update date | 2023-06-02 |
|---|
| Change date | 2017-10-19 |
|---|
| Registry closure date | |
|---|
| Reason for registry closure | |
|---|
| Successor corporate number | |
|---|
| Details of the change | |
|---|
| Latest record | 1 |
|---|
| Excluded from search | 0 |
|---|
| Processing type | 01 |
|---|
| Correction type | 1 |
|---|
| Trade name image ID | |
|---|
| Address image ID | |
|---|
| Sequence number | 2638876 |
|---|
Source: National Tax Agency Corporate Number Publication Site, basic three items
1021001063330
| Corporate number | 1021001063330 |
|---|
| Trade name | Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 |
|---|
| Trade name (kana) | コーディアセラピューティクス |
|---|
| Trade name (alphabet) | |
|---|
| Registry closure date | |
|---|
| Reason for registry closure | |
|---|
| Registered address | 神奈川県藤沢市村岡東２丁目２６番地の１ |
|---|
| Postal code | 2510012 |
|---|
| Prefecture | 神奈川県 |
|---|
| Prefecture code | 14 |
|---|
| City or district | 藤沢市 |
|---|
| City code | 205 |
|---|
| Street address | 村岡東２丁目２６番地の１ |
|---|
| Organisation type | 301 |
|---|
| Processing type | 01 |
|---|
| Correction type | 1 |
|---|
| Status | |
|---|
| Representative | 代表取締役 三宅 洋 |
|---|
| Capital | 876270000 |
|---|
| Employees | 20 |
|---|
| Employees (male) | |
|---|
| Employees (female) | |
|---|
| Business summary | |
|---|
| Website URL | |
|---|
| Year founded | |
|---|
| Business category | |
|---|
| Date established | |
|---|
| Unified government qualification - grade | |
|---|
| Unified government qualification - business items | |
|---|
| Update date | 2023-06-02 |
|---|
| Key information | 1021001063330 |
|---|
Source: gBizINFO (Ministry of Economy, Trade and Industry)
2026-09-22 14:17 (Model: gpt-4.1-nano )
